ICU Medical Inc (ICUI)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $4.48B
Last updated: Nov 17, 2026 at 11:06 AM ET
ICU Medical Inc (ICUI) Financials: Revenue, Profit and Cash Flow
ICU Medical reported revenue of $2.23B for the fiscal year ended Dec 31, 2025, down 6.3% from the year before. That year, net income was $732.00K with a net margin of 0.0%, operating cash flow was $179.85M and free cash flow was $91.80M. The quarter ended Sep 30, 2026 had revenue of $560.44M and net income of $26.85M.
Revenue and Margins
The operating margin was 1.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $379.37M, a compound annual rate of 21.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.23B | -6.3% | 36.8% | 1.9% | 0.0% |
| Dec 2024 | $2.38B | +5.4% | 34.6% | 1.8% | -4.9% |
| Dec 2023 | $2.26B | -0.9% | 32.8% | 1.0% | -1.3% |
| Dec 2022 | $2.28B | +73.2% | 30.6% | -1.9% | -3.3% |
| Dec 2021 | $1.32B | +3.6% | 37.3% | 9.4% | 7.8% |
| Dec 2020 | $1.27B | +0.4% | 36.3% | 7.7% | 6.8% |
| Dec 2019 | $1.27B | -9.6% | 37.3% | 8.5% | 8.0% |
| Dec 2018 | $1.40B | +8.3% | 40.7% | 2.1% | 2.1% |
| Dec 2017 | $1.29B | +240.7% | 33.0% | -1.0% | 5.3% |
| Dec 2016 | $379.37M | N/A | 53.1% | 21.9% | 16.6% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.23B | $2.38B | $2.26B | $2.28B | $1.32B | $1.27B | $1.27B | $1.40B | $1.29B | $379.37M |
| Cost of revenue | $1.41B | $1.56B | $1.52B | $1.58B | $824.82M | $809.51M | $794.34M | $830.01M | $866.52M | $177.97M |
| Gross profit | $822.04M | $824.78M | $739.87M | $697.76M | $491.49M | $461.50M | $471.86M | $570.03M | $426.10M | $201.40M |
| Research and development | $87.50M | $88.61M | $85.34M | $92.98M | $47.50M | $42.95M | $48.61M | $52.87M | $51.25M | $12.96M |
| Operating income | $42.83M | $42.96M | $22.82M | -$42.90M | $123.25M | $98.16M | $107.36M | $29.76M | -$13.29M | $82.94M |
| Net income | $732.00K | -$117.69M | -$29.66M | -$74.29M | $103.14M | $86.87M | $101.03M | $28.79M | $68.64M | $63.08M |
| EBITDA | $311.56M | $277.40M | $274.42M | $244.26M | $221.39M | $190.94M | $192.59M | $98.45M | $120.05M | $105.69M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $560.44M | $551.68M | $530.23M | $540.70M | $536.99M | $548.87M | $604.70M | $629.80M | $589.13M | $596.46M | $566.65M | $587.86M |
| Gross profit | $234.75M | $235.05M | $206.23M | $202.99M | $200.88M | $208.06M | $210.11M | $227.26M | $204.85M | $207.43M | $185.24M | $171.59M |
| Operating income | $52.32M | $39.13M | $13.58M | $5.63M | $13.72M | $10.59M | $12.89M | $37.69M | $8.24M | $7.69M | -$10.65M | -$12.18M |
| Net income | $26.85M | $19.09M | $30.13M | -$15.73M | -$3.40M | $35.34M | -$15.48M | -$23.83M | -$32.98M | -$21.41M | -$39.47M | -$17.15M |
Balance Sheet
As of Dec 2025, total debt of $1.28B exceeded cash and equivalents by $976.70M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.05B | $4.20B | $4.38B | $4.52B | $1.88B | $1.76B | $1.69B | $1.59B | $1.50B | $704.69M |
| Current assets | $1.19B | $1.44B | $1.22B | $1.24B | $1.03B | $920.78M | $882.20M | $927.04M | $864.66M | $569.10M |
| Cash and equivalents | $307.96M | $308.57M | $254.22M | $208.78M | $552.83M | $396.10M | $268.67M | $344.78M | $290.07M | $445.08M |
| Total liabilities | $1.93B | $2.24B | $2.26B | $2.43B | $264.71M | $261.43M | $315.14M | $321.74M | $298.70M | $44.53M |
| Short-term debt | $18.75M | $51.00M | $55.88M | $29.69M | $0 | $26.30M | $0 | $6.15M | $9.06M | N/A |
| Long-term debt | $1.27B | $1.53B | $1.58B | $1.62B | N/A | N/A | N/A | $20.59M | $55.33M | $1.11M |
| Shareholder equity | $2.12B | $1.97B | $2.12B | $2.09B | $1.62B | $1.50B | $1.38B | $1.26B | $1.20B | $660.15M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.94B | $3.97B | $4.01B | $4.05B | $4.10B | $4.11B | $4.18B | $4.20B | $4.31B | $4.29B | $4.29B | $4.38B |
| Total liabilities | $1.75B | $1.82B | $1.90B | $1.93B | $1.98B | $1.99B | $2.20B | $2.24B | $2.26B | $2.25B | $2.22B | $2.26B |
| Cash and equivalents | $301.78M | $298.30M | $288.33M | $307.96M | $299.73M | $300.02M | $289.70M | $308.57M | $312.51M | $302.65M | $251.42M | $254.22M |
| Shareholder equity | $2.19B | $2.15B | $2.11B | $2.12B | $2.13B | $2.12B | $1.99B | $1.97B | $2.05B | $2.04B | $2.07B | $2.12B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 51.0% of operating cash flow. Share repurchases came to 9.6% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $179.85M | $204.03M | $166.20M | -$62.13M | $267.54M | $222.75M | $101.92M | $160.22M | $154.42M | $89.94M |
| Capital expenditures | $88.04M | $79.37M | $83.89M | $90.31M | $68.54M | $92.00M | $97.31M | $92.72M | $74.48M | $23.36M |
| Free cash flow | $91.80M | $124.66M | $82.31M | -$152.44M | $199.00M | $130.75M | $4.61M | $67.50M | $79.94M | $66.58M |
| Dividends paid | N/A | N/A | $9.35M | $10.88M | $1.04M | $317.00K | N/A | N/A | $0 | $0 |
| Share repurchases | $8.77M | $11.99M | $9.35M | $10.88M | $8.34M | $12.88M | $18.64M | $6.25M | $4.06M | $17.23M |
| Investing cash flow | $122.23M | -$88.96M | -$87.95M | -$1.91B | -$90.69M | -$98.14M | -$166.89M | -$103.37M | -$266.87M | $16.28M |
| Financing cash flow | -$311.52M | -$55.80M | -$35.98M | $1.64B | -$16.87M | -$40.00K | -$10.91M | $8.02M | -$44.35M | $2.47M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $99.59M | $80.15M | $38.91M | $60.60M | $56.71M | $11.21M | $51.33M | $40.19M | $36.10M | $81.95M | $45.79M | $91.27M |
| Capital expenditures | $16.19M | $18.51M | $11.30M | $24.65M | $29.08M | $19.70M | $14.62M | $24.08M | $19.91M | $19.47M | $15.91M | $29.94M |
| Free cash flow | $83.40M | $61.64M | $27.61M | $35.95M | $27.63M | -$8.48M | $36.71M | $16.11M | $16.19M | $62.49M | $29.88M | $61.33M |
Frequently Asked Questions About ICUI
What is ICU Medical's annual revenue?
ICU Medical reported revenue of $2.23B for the fiscal year ended Dec 31, 2025.
How fast is ICU Medical's revenue growing?
Revenue was down 6.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.7%.
Is ICU Medical profitable?
Yes. ICU Medical reported net income of $732.00K for the fiscal year ended Dec 31, 2025, with a net margin of 0.0%.
How much free cash flow does ICUI generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $179.85M minus capital expenditures of $88.04M produced free cash flow of $91.80M.
How much debt does ICU Medical have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $1.27B, short-term debt of $18.75M and cash and equivalents of $307.96M.
ICUI pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts